Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion Effect on Seizure Threshold in ECT
NCT03126682Phase 4Completed
- Sponsor
- Duke University
- Start
- Aug 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of bupropion in major depressive disorder (MDD) (2 arms), sponsored by Duke University. Primary endpoints: Change in Seizure Threshold at Day 2 and Change in Seizure Duration at Day 2. Started Aug 2017; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03126682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126682.